Kibio Inc.
Davis, CA
- UEI
- G5JDYJ4F55P5
- CAGE
- 8DG76
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3112 Albany Cir, Davis, CA 95618, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Kibio Inc., a woman-owned small business based in Davis, California, is a federal grant recipient developing peptide-drug conjugate therapeutics and small-molecule oncology treatments under awards from the Defense Health Agency and the National Cancer Institute. The company operates exclusively as a prime recipient on three federal research grants totaling $1.1 million in combined obligated dollars, with no contract prime or subcontractor footprint in the source data.
Kibio's federal grant work centers on oncology drug development. The Defense Health Agency transferred two project grants to Kibio from the University of Texas MD Anderson Cancer Center: a peptide-drug conjugate targeting bone metastatic prostate cancer (awarded September 2023, completion August 2027) and a peptide-drug conjugate for malignant peripheral nerve sheath tumor (awarded September 2022, completion August 2027). The National Cancer Institute awarded a project grant for novel small-molecule therapeutics addressing malignant peripheral nerve sheath tumor (awarded September 2022, completion August 2024). All three awards reflect transferred research initiatives rather than de novo Kibio proposals, suggesting Kibio acquired or absorbed the active research programs and regulatory obligations from MD Anderson.
Customer concentration is heavily skewed toward the Defense Health Agency, which anchors two of the three awards in the source. The National Cancer Institute (part of the Department of Health and Human Services National Institutes of Health) represents the remaining active grant. Two awards face ultimate completion within the next twenty-four months, creating recompete timing for those two efforts. The source contains no federal contract vehicles, no subcontracting activity, and no contract primes — Kibio's federal footprint is grant-only and recipient-only, with no evidence of IDIQs, GWACs, or task-order vehicles. Activity peaked in 2022 with two awards and has slowed to one award in 2023, the most recent award in the source data.
Quick answers
Is Kibio Inc. registered in SAM.gov?
Yes. Kibio Inc.'s SAM.gov registration is active through April 21, 2027.
What is Kibio Inc.'s most recent federal award?
Kibio Inc.'s most recent federal grant award is Peptide drug conjugate as bone targeted therapy for bone metastatic prostate cancer 10JUNE26 modification P00002… (HT94252310203), from Defense Health Agency, on September 1, 2023.
On GovTribe
See Kibio Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors